|Slideshows|December 11, 2014

This Year in Rorschach: 2014

Featuring this year in Rorschach tests at Psychiatric Times.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Psychotherapy and the Prevention of Relapse in Schizophrenia

ByMark L. Ruffalo, MSW, DPsa,Trisha M. Ruffalo, MSW

May 21st 2026

Advances in Ketamine-Assisted Psychotherapy

ByFernando Espí Forcén, MD, PhD

May 19th 2026

Listening

ByRichard M. Berlin, MD

May 13th 2026

Podcast: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders. Optimizing Patient Outcomes With Holly A. Swartz, MD

ByJoseph F. Goldberg, MD,Holly A. Swartz, MD

May 1st 2026

Psychotherapies Can No Longer Afford to Compete With Each Other

ByAllen Frances, MD,Deven Dees

April 28th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

This Year in Rorschach: 2014

Related Content

Psychotherapy and the Prevention of Relapse in Schizophrenia

Advances in Ketamine-Assisted Psychotherapy

Listening

Podcast: The Intersection of Psychotherapy and Psychopharmacology for Mood Disorders. Optimizing Patient Outcomes With Holly A. Swartz, MD

Psychotherapies Can No Longer Afford to Compete With Each Other

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

New Name, New Path for Psychiatry: The Future of the DSM

Endangered Education: Psychiatric Professional Degrees Under Attack